Defining oligometastatic state in uro-oncological cancers

Area of Science:

• Urologic Oncology
• Medical Oncology
• Cancer Research

Background:

• Oligometastatic tumors bridge localized and systemic disease, possessing distinct biological features.
• These tumors are increasingly recognized for their potential for long-term control or cure, driving research in urologic oncology.

Purpose of the Study:

• To review the current understanding and definitions of oligometastatic states in urologic cancers.
• To highlight the clinical significance and future directions in managing oligometastatic urologic tumors.

Main Methods:

• Review of current literature and expert consensus on the definition of oligometastatic disease in prostate, bladder, and kidney cancers.
• Analysis of varying criteria regarding lesion number, organ involvement, and resectability.

Main Results:

• No universal consensus exists for defining oligometastatic prostate cancer (typically 3-5 lesions, limited organ involvement, no visceral metastases).
• Expert consensus defines oligometastatic bladder cancer as up to 3 metastatic lesions suitable for therapy, regardless of organ involvement.
• Oligometastatic kidney cancer is defined by up to 5 metastases, with timing relative to primary tumor diagnosis being significant.

Conclusions:

• Establishing clear definitions for oligometastatic urologic tumors is vital for clinical trials and policy development.
• Standardized definitions will improve patient care and treatment strategies for these distinct cancer states.
• Molecular imaging advancements are anticipated to significantly impact the future management of oligometastatic urologic tumors.